Publications

A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT).

AM Varghese, C Ang, CJ Dimaio, MM Javle, M Gutierrez, N Yarom, ...

A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C)+/-veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g) BRCA/PALB2 …

EM O'Reilly, JW Lee, M Zalupski, M Capanu, J Park, T Golan, E Tahover, ...

A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma

Hayashi A, Fan J, Chen R, Ho YJ, Makohon-Moore AP, Lecomte N, Zhong Y, Hong J, et al.

Abstract CT247: A phase 1/2 study of GB1275, a first-in-class CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with …

A Wang-Gillam, DW Rasco, W Park, E O'Reilly, W Messersmith, ...

Actionable alterations (AA) in gastrointestinal (GI) cancers: Rate of detection and receipt of matched therapies (MT).

M Greally, Y Tuvy, BM Millang, EM O'Reilly, R Yaeger, LB Saltz, GY Ku

Advances in the management of pancreatic adenocarcinoma

EM O’Reilly

Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial

H Algul, M Reni, HL Kindler, P Hammel, E Van Cutsem, T Macarulla, ...

Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial.

M Reni, HL Kindler, P Hammel, E Van Cutsem, T Macarulla, MJ Hall, ...

Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma

McIntyre CA, Lawrence SA, Richards AL, Chou JF, Wong W, Capanu M, … Park W, …

An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice: a review

M Rainone, I Singh, EE Salo-Mullen, ZK Stadler, EM O’Reilly

Artikel online veröffentlicht: 02.11. 2020

EM O’Reilly

Association of coffee intake with survival in patients with advanced or metastatic colorectal cancer

C Mackintosh, C Yuan, FS Ou, S Zhang, D Niedzwiecki, IW Chang, ...

Association of diet quality with survival among people with metastatic colorectal cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial

EL Van Blarigan, S Zhang, FS Ou, A Venlo, K Ng, C Atreya, K Van Loon, ...

Author Correction: Tumour lineage shapes BRCA-mediated phenotypes

P Jonsson, C Bandlamudi, ML Cheng, P Srinivasan, SS Chavan, ...

Author Correction: Tumour lineage shapes BRCA-mediated phenotypes (Nature,(2019), 571, 7766,(576-579), 10.1038/s41586-019-1382-1)

P Jonsson, C Bandlamudi, ML Cheng, P Srinivasan, SS Chavan, ...

Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405

Guercio BJ, Zhang S, Venook AP, Ou FS, Niedzwiecki D, Lenz HJ, Innocenti F, Mullen BC, et al.

BReast CAncer Gene (BRCA) Mutations as an Emerging Biomarker for the Treatment of Gastrointestinal Malignancies

N Premnath, EM O’Reilly

Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial.

M Reni, H Riess, EM O'Reilly, JA Reeves, E Chiorean, TJ George, ...

Diabetes and clinical outcome in patients with metastatic colorectal cancer: CALGB 80405 (Alliance)

JC Brown, S Zhang, FS Ou, AP Venook, D Niedzwiecki, HJ Lenz, ...

Duration of therapy for locally advanced pancreatic cancer: Does it matter?

Tuli R, David J, Lobaugh S, Zhang Z, O'Reilly EM

Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P).

T Macarulla, HL Kindler, P Hammel, M Reni, E Van Cutsem, MJ Hall, ...

Early progression in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) vs placebo (P)

A Reinacher-Schick, T Macarulla, HL Kindler, P Hammel, M Reni, ...

Effect of video-based patient education on pancreatic cancer knowledge and behavior.

W Turell, T Ackbarali, EM O'Reilly, M Alsante, K Pucci, EA Del Nido

Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS …

AR Brannon, G Jayakumaran, M Diosdado, J Patel, A Razumova, Y Hu, ...

Étude de phase II «basket» évaluant l’efficacité de l’anticorps monoclonal bispécifique anti-HER2/HER3 MCLA-128 chez les patients atteints de tumeurs solides avancées …

AM Schram, A Drilon, T Macarulla, EM O’Reilly, J Rodon, B Wolpin, ...

Evolutionary dynamics of non-coding regions in pancreatic ductal adenocarcinoma

A Hayashi, Y Ho, AP Makohon-Moore, A Zucker, J Hong, JG Reiter, ...

Extracellular vesicle and particle biomarkers define multiple human cancers

A Hoshino, HS Kim, L Bojmar, KE Gyan, M Cioffi, J Hernandez, ...

Genetic algorithms to identify homologous recombination deficiency (HRD) in pancreas adenocarcinoma

W Park, J Chen, JF Chou, C Iacobuzio-Donague, N Riaz, EM O'Reilly

Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma

Hayashi A, Yavas A, McIntyre CA, Ho YJ, Erakky A, Wong W, Varghese AM, Melchor JP, et al.

Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection

Park W, Chen J, Chou JF, Varghese AM, Yu KH, Wong W, Capanu M, …

Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings

Maynard H, Stadler ZK, Berger MF, Solit DB, Ly M, Lowery MA, Mandelker D, Zhang L, et al.

Germline mutation prevalence in young adults with cancer

ZK Stadler, A Maio, A Padunan, Y Kemel, E Salo-Mullen, M Sheehan, ...

Impact of prior irinotecan exposure on outcomes of metastatic pancreatic cancer (mPC) patients.

EM O'Reilly, A Surinach, A Dillon, P Cockrum, KH Yu

Landscape of DNA-damage-repair/homologous recombination deficiency (DDR/HRD) in hepatopancreaticobiliary (HPB) cancers.

W Park, E Sokol, J Chen, KH Yu, D Khalil, JJ Harding, IH El Dika, N Riaz, ...

Liver and bile duct cancer

GK Abou-Alfa, W Jarnagin, I El Dika, M D'Angelica, M Lowery, K Brown, ...

Metastatic pancreatic cancer: ASCO guideline update

DPS Sohal, EB Kennedy, P Cinar, T Conroy, MS Copur, CH Crane, ...

Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver

El Dika I, Bowman AS, Berger MF, Capanu M, Chou JF, Benayed R, Zehir A, Shia J, et al.

NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+ 5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in …

A Dean, ZA Wainberg, TS Bekaii-Saab, R Hubner, T Macarulla, ...

NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+ 5-fluorouracil/leucovorin+ oxaliplatin versus nab-paclitaxel+ gemcitabine in patients …

ZA Wainberg, TS Bekaii-Saab, R Hubner, T Macarulla, AS Paulson, ...

Neoadjuvant or adjuvant therapy for resectable or borderline resectable pancreatic cancer: which is preferred?

EM O’Reilly, C Ferrone

Neoadjuvant treatment in patients with resectable and borderline resectable pancreatic cancer

QP Janssen, EM O'Reilly, CHJ Van Eijck, B Groot Koerkamp

New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

Singh RR, O'Reilly EM

Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation …

MJ Hall, T Golan, P Hammel, M Reni, E Van Cutsem, T Macarulla, ...

Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline</i> BRCA<//i …

D Arnold, MJ Hall, T Golan, P Hammel, M Reni, E Van Cutsem, ...

Pancreatic ductal adenocarcinoma (PDAC), BRCA: Detailed analysis and outcomes of cohort from Memorial Sloan Kettering Cancer Center (MSK).

P Momtaz, CA O'Connor, JF Chou, M Capanu, KH Yu, AM Varghese, ...

PD-1 blockade in advanced adrenocortical carcinoma

N Raj, Y Zheng, V Kelly, SS Katz, J Chou, RKG Do, M Capanu, D Zamarin, ...

Pharmacogenomic blood-based assay to predict chemotherapy response and survival in pancreatic cancer.

KH Yu, B McCarthy, WH Isacoff, B Cooper, A Bartlett, J Park, F Purcell, ...

Phase 1b study of a small molecule antagonist of human chemokine (CC motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of …

M Noel, EM O’Reilly, BM Wolpin, DP Ryan, AJ Bullock, CD Britten, ...

Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo)+ BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric …

DY Oh, JA Ajani, YJ Bang, HC Chung, J Lacy, J Lee, T Macarulla, ...

Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo)+ PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric …

AH Ko, J Lee, M ALSINA, JA Ajani, YJ Bang, HC Chung, J Lacy, ...